This Series A funding allows Neuro-Bio to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013. The innovative Neuro-Bio technology is the result of over 40 years of basic research by Baroness Professor Susan Greenfield’s group, initially at Oxford University, that points to a previously unidentified mechanism underlying the continuing cycle of cell death that characterizes the neurodegenerative process. The company has been exploring whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.

Neuro-Bio’s Founder and CEO, Baroness Professor Susan Greenfield commented, “We are delighted to have secured this Series A investment to support the continued growth of our company from start-up to small enterprise. The investment from Kairos is a recognition of our fresh approach as well as the expertise of our team: this investment will increase the possibility of discovery of a novel disruptive treatment that is much needed to improve outcomes for patients with Alzheimer’s.”

Neuro-Bio is taking a new approach to neurodegenerative disorders such as Alzheimer’s Disease. Founded on 40 years of original neuroscience research, they were the first to identify a novel signaling molecule (a peptide ‘T14’) which is significantly elevated in Alzheimer’s brains and drives the cycle of brain cell death in selectively vulnerable cells. As a consequence, it is T14 that is the primary trigger for the production of beta-amyloid and tau which are thus secondary, downstream phenomena. Based on this discovery, Neuro-Bio is developing a system for detection of T14 as a companion biomarker for early diagnosis of neurodegenerative disorders along with novel drug candidates (NBP14 and variants) that could be a completely different type of drug to actually halt the neurodegenerative process. Neuro-Bio has a pipeline of future products that includes other indications such as Parkinson’s and Motor Neurone Disease.

We are very excited about our investment in Neuro-Bio and welcome them to the extended Kairos Ventures family.